Search results

Articles (4)

Journals (0)

1-4 of 4 results for ALK G1202R

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessCase reportFirst published 2020

Acquired multiple mutations ALK I1171N,L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

Jia Hu, Baoshi Zhang, Fangfang Yao [...]

Therapeutic Advances in Respiratory Disease

Open accessCase reportFirst published October, 2025

Durable response with mutation-guided ALK inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report

Sumra S. Chaudhry, D. Ross Camidge, Michael R. Clay [...]

Rare Tumors

Restricted accessCase reportFirst published December, 2024

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs

Rita Leporati, Daniela Miliziano, Teresa Beninato [...]

Tumori Journal

Open accessResearch articleFirst published 2021

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero [...]

Therapeutic Advances in Medical Oncology

Search results

Articles (4)

Journals (0)

1-4 of 4 results for ALK G1202R

Sort by:

Relevance

Select all

Sort by:

Relevance

Open accessCase reportFirst published 2020

Acquired multiple mutations ALK I1171N,L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report

Jia Hu, Baoshi Zhang, Fangfang Yao [...]

Therapeutic Advances in Respiratory Disease

Open accessCase reportFirst published October, 2025

Durable response with mutation-guided ALK inhibition in a patient with metastatic epithelioid inflammatory myofibroblastic sarcoma: A case report

Sumra S. Chaudhry, D. Ross Camidge, Michael R. Clay [...]

Rare Tumors

Restricted accessCase reportFirst published December, 2024

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs

Rita Leporati, Daniela Miliziano, Teresa Beninato [...]

Tumori Journal

Open accessResearch articleFirst published 2021

Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program

Nikolaj Frost, Petros Christopoulos, Diego Kauffmann-Guerrero [...]

Therapeutic Advances in Medical Oncology